HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Recalls Infant Formula Made At Facility FDA Is Investigating For Bacterial Contamination

Executive Summary

Abbott Labs recalls Similac, Alimentum and EleCare brand formula powders made at Sturgis, MI, plant. FDA says complaints about Abbott’s formulas included three reports of Cronobacter sakazakii infections, with one death potentially linked, and one of Salmonella Newport infection.

You may also be interested in...



US FDA Turns To Temporary Enforcement Discretion For Boosting Infant Formula Supply

FDA launches temporary enforcement discretion on infant formula product to help increase supply in US on same day consent decree announced to allow Abbott to restart production at facility closed since February, prompting ongoing formula shortage. 

US Lawmakers Want Answers From FDA On Infant Formula Shortage Following Abbott Recall

House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.

Weighing Shortage Risk, FDA Clears Releasing Metabolic Formulas Made At Abbott’s Closed Plant

With Michigan facility closed as cause of bacterial contamination is investigated, FDA announces “has no objection” to Abbott releasing specialty and metabolic formulas “to individuals needing urgent, life-sustaining supplies” on a case-by-case basis.

Related Content

Related Companies

UsernamePublicRestriction

Register

RS152223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel